Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
← catalyst calendarNCT06632951 · readout ≤ 223 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
150estimated
Sites
37
Countries
Canada, France, Israel +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-20 | actual | When the study began enrolling |
| Primary completion | Mar 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Urothelial Carcinoma
Interventions
- Drug: Livmoniplimab — also filed as ABBV-151
- Drug: Budigalimab — also filed as ABBV-181
- Drug: Docetaxel
- Drug: Paclitaxel
- Drug: Docetaxel
- Drug: Paclitaxel
- Drug: Gemcitabine
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS)
measured Up to Approximately 3.5 Years
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed